Abstract
To evaluate the dilute Russell viper venom time (DRVVT) for the detection of direct-acting oral anticoagulants (DOACs) and to investigate the effect of DOACS on coagulation assays. Patients with DOACs and controls had plasma levels determined by an anti-Xa assay and dilute thrombin clotting time (TCT). Levels were correlated with the DRVVT as well as TCT, prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen, protein C, protein S and antithrombin levels. The utility of the DRVVT for detecting clinically significant levels of DOACs was evaluated. There were 44 samples from patients taking dabigatran, 83 with rivaroxaban, 18 with apixaban and 55 controls. The PT and APTT failed to detect clinically significant doses of anticoagulants adequately. The TCT was increased in patients taking dabigatran and normal in controls and patients on FXa inhibitors. There was a linear correlation with all DOAC levels and the DRVVT, with moderate precision, but it showed high sensitivity (95%) and specificity (90%) for clinically significant DOAC levels. The DRVVT detects clinically significant levels of DOACs and, in conjunction with the TCT, may be used as a screen for the presence and type of DOAC.
References
Aug 6, 2010·Clinical Pharmacology and Therapeutics·T A LeilM Pfister
Apr 5, 2012·American Journal of Hematology·Scott KaatzJack Ansell
Jul 3, 2013·Thrombosis Journal·Wolfgang MueckJan Stampfuss
Oct 1, 2013·Journal of the American College of Cardiology·Paul A ReillyUNKNOWN RE-LY Investigators
Jun 21, 2014·Internal Medicine Journal·H TranC McLintock
Sep 10, 2014·Journal of Thrombosis and Haemostasis : JTH·B J DaleJ W Eikelboom
Sep 19, 2014·Thrombosis and Haemostasis·M Van BlerkP Van de Walle
Nov 27, 2014·Archives of Pathology & Laboratory Medicine·Robert C GosselinStephan Moll
Feb 24, 2015·Seminars in Thrombosis and Hemostasis·Emmanuel J Favaloro, Giuseppe Lippi
Mar 7, 2015·Thrombosis Research·Jonathan DouxfilsFrançois Mullier
May 6, 2015·Pathology·Roslyn BonarKatherine Marsden
Jun 20, 2015·BioMed Research International·Jonathan DouxfilsFrançois Mullier
Feb 26, 2016·Journal of Thrombosis and Haemostasis : JTH·J H LevyUNKNOWN Subcommittee on Control of Anticoagulation
Mar 1, 2016·Journal of Thrombosis and Haemostasis : JTH·L R LetertreP T Onundarson
Mar 30, 2016·Pathology·Roslyn BonarKatherine Marsden
Aug 31, 2016·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN ANNEXA-4 Investigators
Jul 8, 2017·Thrombosis Research·Anne-Laure SennesaelJonathan Douxfils
Jul 12, 2017·The New England Journal of Medicine·Charles V PollackJeffrey I Weitz
Aug 24, 2017·European Journal of Haematology·Kathrine O F JensenHenrik Hansen
Citations
Dec 21, 2018·Therapeutic Drug Monitoring·Eberhard Wieland, Maria Shipkova
Jul 11, 2019·British Journal of Haematology·Sally Cox-MortonWill Thomas
Jun 17, 2020·International Journal of Laboratory Hematology·Thomas ExnerEmmanuel J Favaloro
Mar 19, 2019·Therapeutic Drug Monitoring·Eberhard Wieland, Maria Shipkova
Jan 31, 2019·British Journal of Haematology·Jignesh P PatelRoopen Arya
May 7, 2021·JA Clinical Reports·Kaoru SuzukiShoichi Uezono